With some exceptions, SHP-1-mediated inhibition of RTK signaling in cancer cells is generally associated with antitumor effects, and small molecules that increase SHP-1 expression and induce its activity may still be important candidate anticancer therapeutics. The gene discussed is PTPN6; the disease is cancer.